Cargando…

Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study

BACKGROUND: In assisted reproduction cycles, gonadotropins are administered to obtain a greater number of oocytes. A majority of patients do not have an adverse response; however, approximately 3-6% develop ovarian hyperstimulation syndrome (OHSS). Metformin reduces the risk of OHSS but little is kn...

Descripción completa

Detalles Bibliográficos
Autores principales: Elia, Evelin M, Quintana, Ramiro, Carrere, Carlos, Bazzano, María V, Rey-Valzacchi, Gastón, Paz, Dante A, Pustovrh, María C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851870/
https://www.ncbi.nlm.nih.gov/pubmed/24011132
http://dx.doi.org/10.1186/1757-2215-6-62
_version_ 1782294371474866176
author Elia, Evelin M
Quintana, Ramiro
Carrere, Carlos
Bazzano, María V
Rey-Valzacchi, Gastón
Paz, Dante A
Pustovrh, María C
author_facet Elia, Evelin M
Quintana, Ramiro
Carrere, Carlos
Bazzano, María V
Rey-Valzacchi, Gastón
Paz, Dante A
Pustovrh, María C
author_sort Elia, Evelin M
collection PubMed
description BACKGROUND: In assisted reproduction cycles, gonadotropins are administered to obtain a greater number of oocytes. A majority of patients do not have an adverse response; however, approximately 3-6% develop ovarian hyperstimulation syndrome (OHSS). Metformin reduces the risk of OHSS but little is known about the possible effects and mechanisms of action involved. OBJECTIVE: To evaluate whether metformin attenuates some of the ovarian adverse effects caused by OHSS and to study the mechanisms involved. MATERIAL AND METHODS: A rat OHSS model was used to investigate the effects of metformin administration. Ovarian histology and follicle counting were performed in ovarian sections stained with Masson trichrome. Vascular permeability was measured by the release of intravenously injected Evans Blue dye (EB). VEGF levels were measured by commercially immunosorbent assay kit. COX-2 protein expression was evaluated by western blot and NOS levels were analyses by immunohistochemistry. RESULTS: Animals of the OHSS group showed similar physiopathology characteristics to the human syndrome: increased body weight, elevated progesterone and estradiol levels (P<0.001), increased number of corpora lutea (P<0.001), higher ovarian VEGF levels and vascular permeability (P<0.001 and P<0.01); and treatment with metformin prevented this effect (OHSS+M group; P<0.05). The vasoactive factors: COX-2 and NOS were increased in the ovaries of the OHSS group (P<0.05 and P<0.01) and metformin normalized their expression (P<0.05); suggesting that metformin has a role preventing the increased in vascular permeability caused by the syndrome. CONCLUSION: Metformin has a beneficial effect preventing OHSS by reducing the increase in: body weight, circulating progesterone and estradiol and vascular permeability. These effects of metformin are mediated by inhibiting the increased of the vasoactive molecules: VEGF, COX-2 and partially NOS. Molecules that are increased in OHSS and are responsible for a variety of the symptoms related to OHSS.
format Online
Article
Text
id pubmed-3851870
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38518702013-12-06 Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study Elia, Evelin M Quintana, Ramiro Carrere, Carlos Bazzano, María V Rey-Valzacchi, Gastón Paz, Dante A Pustovrh, María C J Ovarian Res Research BACKGROUND: In assisted reproduction cycles, gonadotropins are administered to obtain a greater number of oocytes. A majority of patients do not have an adverse response; however, approximately 3-6% develop ovarian hyperstimulation syndrome (OHSS). Metformin reduces the risk of OHSS but little is known about the possible effects and mechanisms of action involved. OBJECTIVE: To evaluate whether metformin attenuates some of the ovarian adverse effects caused by OHSS and to study the mechanisms involved. MATERIAL AND METHODS: A rat OHSS model was used to investigate the effects of metformin administration. Ovarian histology and follicle counting were performed in ovarian sections stained with Masson trichrome. Vascular permeability was measured by the release of intravenously injected Evans Blue dye (EB). VEGF levels were measured by commercially immunosorbent assay kit. COX-2 protein expression was evaluated by western blot and NOS levels were analyses by immunohistochemistry. RESULTS: Animals of the OHSS group showed similar physiopathology characteristics to the human syndrome: increased body weight, elevated progesterone and estradiol levels (P<0.001), increased number of corpora lutea (P<0.001), higher ovarian VEGF levels and vascular permeability (P<0.001 and P<0.01); and treatment with metformin prevented this effect (OHSS+M group; P<0.05). The vasoactive factors: COX-2 and NOS were increased in the ovaries of the OHSS group (P<0.05 and P<0.01) and metformin normalized their expression (P<0.05); suggesting that metformin has a role preventing the increased in vascular permeability caused by the syndrome. CONCLUSION: Metformin has a beneficial effect preventing OHSS by reducing the increase in: body weight, circulating progesterone and estradiol and vascular permeability. These effects of metformin are mediated by inhibiting the increased of the vasoactive molecules: VEGF, COX-2 and partially NOS. Molecules that are increased in OHSS and are responsible for a variety of the symptoms related to OHSS. BioMed Central 2013-09-08 /pmc/articles/PMC3851870/ /pubmed/24011132 http://dx.doi.org/10.1186/1757-2215-6-62 Text en Copyright © 2013 Elia et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Elia, Evelin M
Quintana, Ramiro
Carrere, Carlos
Bazzano, María V
Rey-Valzacchi, Gastón
Paz, Dante A
Pustovrh, María C
Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study
title Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study
title_full Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study
title_fullStr Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study
title_full_unstemmed Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study
title_short Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study
title_sort metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851870/
https://www.ncbi.nlm.nih.gov/pubmed/24011132
http://dx.doi.org/10.1186/1757-2215-6-62
work_keys_str_mv AT eliaevelinm metformindecreasestheincidenceofovarianhyperstimulationsyndromeanexperimentalstudy
AT quintanaramiro metformindecreasestheincidenceofovarianhyperstimulationsyndromeanexperimentalstudy
AT carrerecarlos metformindecreasestheincidenceofovarianhyperstimulationsyndromeanexperimentalstudy
AT bazzanomariav metformindecreasestheincidenceofovarianhyperstimulationsyndromeanexperimentalstudy
AT reyvalzacchigaston metformindecreasestheincidenceofovarianhyperstimulationsyndromeanexperimentalstudy
AT pazdantea metformindecreasestheincidenceofovarianhyperstimulationsyndromeanexperimentalstudy
AT pustovrhmariac metformindecreasestheincidenceofovarianhyperstimulationsyndromeanexperimentalstudy